ESR1 and breast cancer: Triple negative breast cancer (TNBC), a special clinical pathological subtype of breast cancer with negative expressions of estrogen receptor (ER), progesterone receptor (PR), and HER-2 [8], accounts for about 10 to 20% of breast cancer.